Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

69
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
69
Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

365
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
365
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

127
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
127
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

71
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
71
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

97
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Use of Generative Artificial Intelligence in Systematic Literature Reviews: A Rapid Review of the Literature.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Domains in Health Technology Assessment of Digital Health Technologies: A Mapping Review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

DrugUtilisation: An R Package to Support Drug Utilisation Research Using the OMOP Common Data Model.

Pharmacoepidemiology and drug safety·2026
Same author

Extracting and Classifying Drug Discontinuations From Estonian Electronic Health Records: Development and Validation Study.

Journal of medical Internet research·2026
Same author

Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.

Diabetes, obesity & metabolism·2026
Same author

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study.

Ophthalmology·2026

Related Experiment Video

Updated: Jul 1, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Markov modeling for cost-effectiveness using federated health data network.

Markus Haug1, Marek Oja1, Maarja Pajusalu1

  • 1Institute of Computer Science, University of Tartu, Tartu 51009, Estonia.

Journal of the American Medical Informatics Association : JAMIA
|March 13, 2024
PubMed
Summary

New R-packages standardize health economics research on OMOP data networks. Telemonitoring for heart failure was found not cost-effective across international sites.

Keywords:
Markov chainsOHDSI CDMcost-effectivenessobservational datatreatment trajectories

More Related Videos

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

798
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Related Experiment Videos

Last Updated: Jul 1, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

798
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Area of Science:

  • Health economics
  • Health informatics
  • Pharmacoeconomics

Background:

  • Cost-effectiveness analysis (CEA) in healthcare lacks standardized tools, often relying on ad-hoc methods and limited, site-specific data.
  • Published CEA results can lack generalizability due to narrow focus and partial decision criteria, hindering international comparisons.
  • The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) provides a framework for harmonized health data, but tools for health economic modeling are needed.

Purpose of the Study:

  • To introduce two R-packages designed to standardize and improve the reproducibility, transparency, and transferability of health economic models using OMOP-based data networks.
  • To facilitate health economics research by providing tools for state definitions, database interaction, Markov model learning, and profile synthesis.
  • To demonstrate the utility of these R-packages in a multisite, international health economic evaluation.

Main Methods:

  • Development of two R-packages: one for managing state definitions and database interaction, and another for Markov model learning and profile synthesis.
  • Replication of a UK-based heart failure cost-effectiveness analysis across five international OMOP CDM databases (Estonia, Spain, Serbia, USA).
  • Examination of treatment trajectories for 47,163 patients comparing telemonitoring to standard care.

Main Results:

  • The overall incremental cost-effectiveness ratio (ICER) for telemonitoring versus standard care was 57,472 €/QALY.
  • Country-specific ICERs ranged from 40,372 €/QALY (Serbia) to 90,893 €/QALY (USA), all exceeding typical willingness-to-pay thresholds.
  • The analysis, facilitated by the R-packages, indicated that telemonitoring for heart failure was not cost-effective in the studied populations.

Conclusions:

  • The developed R-packages successfully enable standardized and reproducible cost-effectiveness analysis on OMOP CDM data networks.
  • The study highlights the not cost-effective nature of telemonitoring for heart failure across diverse international healthcare settings.
  • These tools advance the field of health economics by promoting robust, transferable, and transparent model development and application.